Targeted treatment of anerobic cancer
The present invention relates to a pharmaceutical cocktail and methods of treatment involving said cocktail, in particular, a combination of effective amounts of a carbonic anhydrase inhibitor, in combination with effective amounts of an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab for the treatment of cancer. In other embodiments, it relates to compositions and methods of treating cancer involving effective amounts of a carbonic anhydrase inhibitor. Pharmaceutical compositions and methods of treating cancer (eliminating the tumor, shrinking the tumor, prolonging the life of the patient, increasing quality of life by decreasing the grade of adverse events seen with other cancer treatments, and/or preventing/reducing the likelihood of the tumor's metastases) are additional aspects of the present invention. In addition, the present invention may be used to favorably impact the therapeutic result of patients who have not responded to alternative, traditional anti-cancer therapy.
1. A method of treating cancer comprising administering to a patient an effective amount of a loop diuretic and an angiogenesis inhibitor, wherein said patient has metastases and said administration reduces metastases of said cancer.
2. The method according to claim 1 wherein said angiogenesis inhibitor is a humanized monoclonal antibody.
3. The method of claim 2 , wherein said antibody is bevacizumab.
4. The method according to claim 1 wherein said treating comprises repeated administration of at least one of the loop diuretic and angiogenesis inhibitor.
5. The method according to claim 1 wherein said loop diuretic is bumetanide.
6. The method according to claim 1 wherein said cancer is hypoxic cancer.
7. The method according to claim 1 wherein said administering results in the shrinkage of said cancer.
8. A pharmaceutical composition comprising an effective amount of a loop diuretic and an angiogenesis inhibitor, wherein said angiogenesis inhibitor is bevacizumab.
9. The composition according to claim 8 wherein said loop diuretic is bumetanide.
10. The composition according to claim 8 formulated for intravenous administration.
11. A pharmaceutical composition comprising an effective amount of a loop diuretic and an angiogenesis inhibitor, wherein said loop diuretic is bumetanide.
12. The composition according to claim 11 , formulated for intravenous administration.
13. The composition according to claim 11 , wherein said angiogenesis inhibitor is bevacizumab.